IMMUNIC, INC. 8-K

What Happened
Immunic, Inc. (IMUX) announced that on January 5, 2026 Nasdaq approved its application to transfer the company's common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market. The transfer takes effect at the opening of business on January 7, 2026; the stock will continue to trade under the symbol "IMUX." Nasdaq has granted Immunic an additional 180‑day period to regain compliance with the $1.00 minimum bid price rule.

Key Details

• Nasdaq approval date: January 5, 2026; listing transfer effective January 7, 2026.
• Original noncompliance notice received June 27, 2025 for Rule 5450(a)(1) (closing bid below $1.00 for 30 consecutive business days).
• Initial 180‑day cure period expired December 24, 2025; company had not regained compliance.
• New compliance deadline: on or before June 22, 2026, Immunic must have a minimum $1.00 bid price for at least 10 consecutive business days.
• As a condition of approval (Nasdaq Listing Rule 5810(c)(3)(a)(i)), Immunic informed Nasdaq it may seek a reverse stock split if necessary.
• If compliance is not regained, Nasdaq may initiate delisting; Immunic could appeal to a Nasdaq Listing Qualifications Panel.

Why It Matters
The transfer to the Nasdaq Capital Market preserves continued Nasdaq trading for IMUX while giving the company additional time to fix its sub‑$1 share price. For investors, the key near‑term implications are the June 22, 2026 compliance deadline and the potential for a reverse stock split, which could affect share counts and per‑share metrics. Failure to meet the bid‑price requirement could lead to delisting proceedings, although the company would have an appeal opportunity.